Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

2017403 citationsJournal Articlegreen Open Access

Authors

Steven Le Gouill · Centre National de la Recherche Scientifique

Catherine Thiéblemont · Centre National de la Recherche Scientifique

Lucie Obéric · Institut universitaire du cancer de Toulouse Oncopole

Philippe Moreau · Centre National de la Recherche Scientifique

Krimo Bouabdallah · Université Paris-Sud

Caroline Dartigeas · Inserm

Gandhi Damaj

Abstract

Rituximab maintenance therapy after transplantation prolonged event-free survival, progression-free survival, and overall survival among patients with mantle-cell lymphoma who were younger than 66 years of age at diagnosis. (Funded by Roche and Amgen; LyMa ClinicalTrials.gov number, NCT00921414 .).

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Cutaneous lymphoproliferative disorders research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 13, pp. 1250-1260

DOI: 10.1056/nejmoa1701769

Field-Weighted Citation Impact: 26.72